Advertisement

Topics

Motif Bio higher as it presents data from Phase III iclaprim trial

08:15 EDT 16 Apr 2019 | Proactive Investors

The presentation provided a drill-down in the results from the company’s REVIVE study

Original Article: Motif Bio higher as it presents data from Phase III iclaprim trial

NEXT ARTICLE

More From BioPortfolio on "Motif Bio higher as it presents data from Phase III iclaprim trial"

Advertisement
Quick Search
Advertisement
Advertisement